Cancer Drug Bet Pays Off for Biotech CEO With 3,600% Stock Surge, , on September 30, 2020 at 3:01 pm

Financial News
By
On September 30, 2020
In Financial News
Tags:

(Bloomberg) — When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards.It was the gamble of a lifetime for the 53-year-old CEO, who decided to shutter the drug developer’s lead program on treating tumors directly and instead focus on cancer-fighting technology for patients with different blood cancers. Investors cheered, rewarding him with a 3,600% stock-surge since he joined the company a year ago.Trillium is the No. 1 stock on Canada’s S&P/TSX Composite Index this year, skyrocketing past tech behemoth Shopify Inc. by almost 10-fold. It’s U.S.-listed shares are the fourth best-performing company on the Nasdaq Composite Index.Despite its epic stock-market rally, every analyst covering the company rates it a buy, signaling that further gains are on the horizon for investors that missed out on Trillium’s initial boom. Wall Street has an average 12-month share price target of $17.58, implying gains of about 30% over the coming year, data compiled by Bloomberg show. Trillium’s shares closed trading at $13.55 on Tuesday.“We need to walk before we run, but if you ask me what our ultimate aspirations are, it’s to challenge chemotherapy,” Skvarka, a former partner of Bain & Co. and Harvard Business School graduate, said by phone.The rebirth of Cambridge, Massachusetts-based Trillium attracted a who’s who of health-focused hedge funds and snagged a $25 million investment from industry giant Pfizer Inc. For Skvarka, who celebrated the anniversary of his first year last weekend, the decision to restructure the company and focus on a newer cancer technology has transformed the drugmaker into a firm with a market cap of about $1.3 billion. Last Halloween, it had a value of a mere $7 million.Some of the hedge funds that have invested in the company, like Millennium Management LLC and Avoro Capital Advisors, have cashed in on part of the year’s gains, while others including Ghost Tree Capital LLC have piled onto their positions.Trillium, like many drug-developing peers that are focused on cancer therapies, is looking to improve on current treatment options and help patients live longer lives.“It’s a very exciting time,” Skvarka said. “We are squarely out of the realm of preclinical data and in the realm of clinical data.”M&A Target?Those aspirations are where the company’s cancer medicines, TTI-621 and TTI-622, come in. The pair of programs, which have shown promising results in early stage studies, are in an emerging class of cancer-fighting technologies that triggered Gilead Sciences Inc.’s $4.9 billion takeout of peer Forty Seven Inc. earlier this year. That deal has sparked speculation that Trillium could be among the next group of companies snatched up by bigger players amid the industry’s rush of deals.While Skvarka wouldn’t comment on whether the company has been approached about a sale, he said that Trillium’s goal is to keep its options open for the time being.“The way we struck the Pfizer deal was very important for us as it kept our optionality open” for the future, he said. “I am a big believer of optionality and having as many options as possible. The options for us are to continue alone or strike a global partnership potentially a way down the road.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Cancer Drug Bet Pays Off for Biotech CEO With 3,600% Stock Surge(Bloomberg) — When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards.It was the gamble of a lifetime for the 53-year-old CEO, who decided to shutter the drug developer’s lead program on treating tumors directly and instead focus on cancer-fighting technology for patients with different blood cancers. Investors cheered, rewarding him with a 3,600% stock-surge since he joined the company a year ago.Trillium is the No. 1 stock on Canada’s S&P/TSX Composite Index this year, skyrocketing past tech behemoth Shopify Inc. by almost 10-fold. It’s U.S.-listed shares are the fourth best-performing company on the Nasdaq Composite Index.Despite its epic stock-market rally, every analyst covering the company rates it a buy, signaling that further gains are on the horizon for investors that missed out on Trillium’s initial boom. Wall Street has an average 12-month share price target of $17.58, implying gains of about 30% over the coming year, data compiled by Bloomberg show. Trillium’s shares closed trading at $13.55 on Tuesday.“We need to walk before we run, but if you ask me what our ultimate aspirations are, it’s to challenge chemotherapy,” Skvarka, a former partner of Bain & Co. and Harvard Business School graduate, said by phone.The rebirth of Cambridge, Massachusetts-based Trillium attracted a who’s who of health-focused hedge funds and snagged a $25 million investment from industry giant Pfizer Inc. For Skvarka, who celebrated the anniversary of his first year last weekend, the decision to restructure the company and focus on a newer cancer technology has transformed the drugmaker into a firm with a market cap of about $1.3 billion. Last Halloween, it had a value of a mere $7 million.Some of the hedge funds that have invested in the company, like Millennium Management LLC and Avoro Capital Advisors, have cashed in on part of the year’s gains, while others including Ghost Tree Capital LLC have piled onto their positions.Trillium, like many drug-developing peers that are focused on cancer therapies, is looking to improve on current treatment options and help patients live longer lives.“It’s a very exciting time,” Skvarka said. “We are squarely out of the realm of preclinical data and in the realm of clinical data.”M&A Target?Those aspirations are where the company’s cancer medicines, TTI-621 and TTI-622, come in. The pair of programs, which have shown promising results in early stage studies, are in an emerging class of cancer-fighting technologies that triggered Gilead Sciences Inc.’s $4.9 billion takeout of peer Forty Seven Inc. earlier this year. That deal has sparked speculation that Trillium could be among the next group of companies snatched up by bigger players amid the industry’s rush of deals.While Skvarka wouldn’t comment on whether the company has been approached about a sale, he said that Trillium’s goal is to keep its options open for the time being.“The way we struck the Pfizer deal was very important for us as it kept our optionality open” for the future, he said. “I am a big believer of optionality and having as many options as possible. The options for us are to continue alone or strike a global partnership potentially a way down the road.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

+65 3105 1295

Taiwan

Coming Soon!

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Follow Us

Market Coverage